Access & reimbursement

Cardiac rehab saves lives. Health systems still treat it like optional aftercare

BMI is not enough. Cardiometabolic risk is hiding in where fat lives

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved

Japan Approves MRD Testing. Price Will Decide Whether Patients Can Use It.
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.

A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.

Gene therapy is entering cardiology. Friedreich ataxia shows why rare heart disease may be the first test

Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.

When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
